Avidity Biosciences RNA
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Avidity Biosciences (RNA) Business Model and Operations Summary
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Key Insights
Avidity Biosciences (RNA) Core Market Data and Business Metrics
Latest Closing Price
$26.74Market Cap
$3.25 BillionPrice-Earnings Ratio
-9.28Total Outstanding Shares
120.21 Million SharesTotal Employees
391Dividend
No dividendIPO Date
June 12, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
10578 Science Center Drive, San Diego, CA, 92121
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $287.04 Million |
| Net Cash Flow From Investing Activities | $-738.99 Million |
| Net Cash Flow From Operating Activities, Continuing | $-184.50 Million |
| Net Cash Flow From Financing Activities | $1.21 Billion |
| Net Cash Flow | $287.04 Million |
| Net Cash Flow From Financing Activities, Continuing | $1.21 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-280.49 Million |
| Operating Expenses | $334.81 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Diluted Average Shares | $106.93 Million |
| Benefits Costs and Expenses | $290.61 Million |
| Research and Development | $260.79 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $8.98 Million |
| Comprehensive Income/Loss | $-271.51 Million |
| Other Comprehensive Income/Loss | $8.98 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-271.51 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Assets | $9.41 Million |
| Cash | $1.60 Billion |
| Other Current Assets | $7.80 Million |
| Equity Attributable To Parent | $1.50 Billion |
| Assets | $1.64 Billion |
| Prepaid Expenses | $14.06 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||